Canadian Study of Arterial Inflammation in Patients With Diabetes and Vascular Events: EvaluatioN of Colchicine
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Cardiovascular Disease (CVD) is a leading cause of death in the developed world.
Atherosclerosis causes plaques in the blood vessels and is a common form of CVD. Inflammation
is now recognized as a major cause of atherosclerosis. Therapies that target inflammation are
being examined as a potential treatment option. Imaging to detect inflammation may be a
solution to understand mechanisms and to optimize patient selection and outcomes for these
drugs. Fluorodeoxyglucose (FDG) PET imaging can detect inflammation in the plaque and
identify patients vulnerable to plaque rupture which cause events such as myocardial
infarctions (MI) and strokes. The primary objective of this proposal(CADENCE) is to determine
if the drug colchicine has an effect on plaque inflammation in patients at high risk for
events (patients with diabetes or pre-diabetes and recent myocardial infarction, stroke or
transient ischemic attacks (TIAs)). This mechanistic and proof-of-concept study will set the
stage for future studies that will determine if inflammation imaging can be integrated into
clinical practice to personalize decisions for anti-inflammation therapies.